Evidence from clinical trials has also shown a significant remission improvement along with prolonged OS, which indicates the successful use of these FLT3 inhibitors to treat refractory or relapsed AML harboring FLT3-ITD mutations. This evidence concerns the gene FLT3 and acute myeloid leukemia.